The real meat is the actual mechanism by which Optina (Danazol) works.
The Retina Today scientific staff of skilled scientists reviewed the article and they were certainly far more skilled than any morons writing comments and blogs on Ampio, and their conclusion is that Optina actually repairs the leaking blood vessels. In fact, it works almost instantly. AND ITS A PILL! It takes a truly skilled scientist to understand the mechanism of the f actin cortical ring structure that is impacted by Optina and that is why Optina is going to succeed and displace Eylea. There is absolutely no misunderstanding about that simple fact.
And Ampion and Zertane are right their beside Optina getting ready to soar!
Let all the wannabee scientists who need their egos stroked make all the noise they want because they just make themselves appear quite foolish and nobody listens to them anyway.
Ampio is going to be a very large company very soon and all its growth will be internal from its drugs.
Let's hope all the naysayers are short and even short more. YAHOO!!!
This is going to be very very entertaining. And very very painful for those on the short side because this little company has very little stock outstanding.
Oral administration of danazol to patients with DME is safe with no evidence of serious adverse events. Danazol appears to reduce DME in a BMI dosage-adjusted manner and appears to trend toward improved visual acuity, although the trial described here was too small to make this definitive conclusion. Our in vitro data suggest that danazol has a biphasic effect on endothelial cells: At low doses, danazol decreases vascular leakage, while at higher concentrations an increase in vascular permeability is observed. This biphasic effect was supported by the effectiveness of danazol in vivo at different BMIs. A US Food and Drug Administration phase 2b trial is in progress to further the understanding and approval of this promising drug for a highly prevalent and debilitating condition."
It makes no claims that danazol works for DME, and says " the trial described here was too small to make this definitive conclusion".
Oddly, the article also says "A US Food and Drug Administration phase 2b trial is in progress to further the understanding and approval of this promising drug for a highly prevalent and debilitating condition.". Since the Retina Today article was on the study at St. Michaels, where was this Phase 2b study done?